ADPT
VENTE TOTALE: 764 969 titres (~19 024 608,06 $ US)
- Insiders
- OWEN KATEY EINTERZ, HERSHBERG ROBERT, ROBINS CHAD M, NEUPERT PETER M
- Total bought
- —
- Total sold
- $19,024,608
- Last activity
- 2026-08-26
- Last synced
-
2026-09-01 10:09:45
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-01
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 74.2% | 59.7% | 55.6% | 68.7% | 68.1% | |
| Ebit Margin | -17.2% | -82.7% | -124.2% | -105.8% | -134.3% | |
| Ebitda Margin | -10.8% | -71.9% | -111.2% | -94.6% | -125.3% | |
| Operating Profit Margin | -20.6% | -90.8% | -133.3% | -108.0% | -135.4% | |
| Pretax Profit Margin | -21.5% | -89.2% | -132.3% | -108.1% | -134.3% | |
| Continuous Operations Profit Margin | -21.5% | -89.2% | -132.3% | -108.1% | -134.3% | |
| Net Profit Margin | -21.5% | -89.1% | -132.3% | -108.0% | -134.3% | |
| Bottom Line Profit Margin | -21.5% | -89.1% | -132.3% | -108.0% | -134.3% | |
| Current Ratio | 3.339 | 2.894 | 4.660 | 5.120 | 3.539 | |
| Quick Ratio | 3.229 | 2.808 | 4.496 | 4.989 | 3.370 | |
| Solvency Ratio | -0.145 | -0.416 | -0.575 | -0.457 | -0.606 | |
| Cash Ratio | 0.784 | 0.489 | 0.739 | 0.820 | 1.222 | |
| Price To Earnings Ratio | -41.641 | -5.556 | -3.141 | -7.640 | -19.219 | |
| Price To Earnings Growth Ratio | 0.652 | 0.181 | -0.056 | 0.242 | -0.509 | |
| Forward Price To Earnings Growth Ratio | 0.652 | 0.181 | -0.056 | 0.242 | -0.509 | |
| Price To Earnings Diluted Ratio | -41.641 | -5.556 | -3.141 | -7.640 | -19.219 | |
| Price To Earnings Diluted Growth Ratio | 0.652 | 0.181 | -0.056 | 0.242 | -0.509 | |
| Price To Book Ratio | 11.262 | 4.354 | 2.294 | 2.346 | 6.521 | |
| Price To Sales Ratio | 8.896 | 4.932 | 4.155 | 5.876 | 25.517 | |
| Price To Free Cash Flow Ratio | -50.341 | -8.926 | -4.236 | -5.436 | -15.477 | |
| Price To Operating Cash Flow Ratio | -53.581 | -9.270 | -4.526 | -5.919 | -20.435 | |
| Debt To Assets Ratio | 0.547 | 0.166 | 0.149 | 0.126 | 0.121 | |
| Debt To Equity Ratio | 1.282 | 0.441 | 0.320 | 0.233 | 0.185 | |
| Debt To Capital Ratio | 0.562 | 0.306 | 0.243 | 0.189 | 0.156 | |
| Long Term Debt To Capital Ratio | 0.474 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 2.343 | 2.661 | 2.144 | 1.846 | 1.529 | |
| Working Capital Turnover Ratio | 1.399 | 0.705 | 0.440 | 0.500 | 0.339 | |
| Operating Cash Flow Ratio | -0.511 | -0.971 | -1.776 | -1.675 | -1.693 | |
| Operating Cash Flow Sales Ratio | -0.166 | -0.532 | -0.918 | -0.993 | -1.249 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.064 | 1.038 | 1.068 | 1.089 | 1.320 | |
| Debt Service Coverage Ratio | -1.178 | -11.119 | -13.715 | -41.343 | 0.000 | |
| Interest Coverage Ratio | -4.850 | -14.037 | -16.452 | -47.236 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -3.391 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.164 | -1.065 | -1.583 | -1.703 | -1.725 | |
| Capital Expenditure Coverage Ratio | -15.541 | -25.986 | -14.614 | -11.251 | -3.121 | |
| Dividend Paid And Capex Coverage Ratio | -15.541 | -25.986 | -14.614 | -11.251 | -3.121 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -89.595 | -7.177 | -3.916 | -6.317 | -20.228 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 74.2% | ▲14.5% | ▲9.0% |
| Ebit Margin | -17.2% | ▲65.5% | ▲75.6% |
| Ebitda Margin | -10.8% | ▲61.2% | ▲72.0% |
| Operating Profit Margin | -20.6% | ▲70.2% | ▲77.0% |
| Pretax Profit Margin | -21.5% | ▲67.7% | ▲75.6% |
| Continuous Operations Profit Margin | -21.5% | ▲67.7% | ▲75.6% |
| Net Profit Margin | -21.5% | ▲67.6% | ▲75.6% |
| Bottom Line Profit Margin | -21.5% | ▲67.6% | ▲75.6% |
| Current Ratio | 3.338 | ▲0.445 | ▼-0.572 |
| Quick Ratio | 3.229 | ▲0.421 | ▼-0.549 |
| Solvency Ratio | -0.145 | ▲0.272 | ▲0.295 |
| Cash Ratio | 0.784 | ▲0.295 | ▼-0.027 |
| Price To Earnings Ratio | -41.641 | ▼-36.086 | ▼-26.202 |
| Price To Earnings Growth Ratio | 0.652 | ▲0.471 | ▲0.550 |
| Forward Price To Earnings Growth Ratio | 0.652 | ▲0.471 | ▲0.550 |
| Price To Earnings Diluted Ratio | -41.641 | ▼-36.086 | ▼-26.202 |
| Price To Earnings Diluted Growth Ratio | 0.652 | ▲0.471 | ▲0.550 |
| Price To Book Ratio | 11.262 | ▲6.907 | ▲5.906 |
| Price To Sales Ratio | 8.896 | ▲3.964 | ▼-0.979 |
| Price To Free Cash Flow Ratio | -50.342 | ▼-41.415 | ▼-33.458 |
| Price To Operating Cash Flow Ratio | -53.581 | ▼-44.311 | ▼-34.835 |
| Debt To Assets Ratio | 0.547 | ▲0.382 | ▲0.325 |
| Debt To Equity Ratio | 1.282 | ▲0.842 | ▲0.790 |
| Debt To Capital Ratio | 0.562 | ▲0.256 | ▲0.271 |
| Long Term Debt To Capital Ratio | 0.473 | ▲0.473 | ▲0.379 |
| Financial Leverage Ratio | 2.344 | ▼-0.317 | ▲0.239 |
| Working Capital Turnover Ratio | 1.399 | ▲0.694 | ▲0.723 |
| Operating Cash Flow Ratio | -0.511 | ▲0.460 | ▲0.814 |
| Operating Cash Flow Sales Ratio | -0.166 | ▲0.366 | ▲0.606 |
| Free Cash Flow Operating Cash Flow Ratio | 1.064 | ▲0.026 | ▼-0.052 |
| Debt Service Coverage Ratio | -1.178 | ▲9.941 | ▲12.293 |
| Interest Coverage Ratio | -4.850 | ▲9.187 | ▲11.665 |
| Short Term Operating Cash Flow Coverage Ratio | -3.391 | ▼-3.391 | ▼-2.713 |
| Operating Cash Flow Coverage Ratio | -0.164 | ▲0.901 | ▲1.084 |
| Capital Expenditure Coverage Ratio | -15.541 | ▲10.445 | ▼-1.438 |
| Dividend Paid And Capex Coverage Ratio | -15.541 | ▲10.445 | ▼-1.438 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -89.595 | ▼-82.418 | ▼-64.148 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.46B | $882.6M | $707.5M | $1.09B | $3.94B | |
| Enterprise value | $2.67B | $924.1M | $741.2M | $1.11B | $3.91B | |
| EV / Sales | 9.65x | 5.16x | 4.35x | 5.97x | 25.34x | |
| EV / Op. cash flow | -58.15x | -9.71x | -4.74x | -6.02x | -20.29x | |
| EV / Free cash flow | -54.63x | -9.35x | -4.44x | -5.53x | -15.37x | |
| EV / EBITDA | -89.59x | -7.18x | -3.92x | -6.32x | -20.23x | |
| Net debt / EBITDA | -7.04x | -0.32x | -0.18x | -0.10x | 0.14x | |
| Current ratio | 3.34x | 2.89x | 4.66x | 5.12x | 3.54x | |
| Income quality | 0.77x | 0.60x | 0.69x | 0.92x | 0.93x | |
| Graham net-net | -$0 | -$1 | $0 | $1 | $0 | |
| Tax burden | 100.1% | 99.9% | 100.0% | 99.9% | 100.0% | |
| Interest burden | 124.7% | 107.8% | 106.5% | 102.2% | 100.0% | |
| Working capital | $210.3M | $185.7M | $322.2M | $452.4M | $288.9M | |
| Invested capital | $405.7M | $402.5M | $566.6M | $742.4M | $589.4M | |
| Return on assets | -11.6% | -29.6% | -34.1% | -23.4% | -22.4% | |
| Operating ROA | -10.9% | -27.1% | -29.9% | -22.5% | -20.5% | |
| Return on tangible assets | -15.2% | -38.2% | -41.9% | -27.4% | -26.0% | |
| Return on equity | -27.2% | -78.7% | -73.0% | -43.1% | -34.3% | |
| Return on invested capital | -13.1% | -36.0% | -39.0% | -26.5% | -25.7% | |
| Return on capital employed | -13.5% | -36.8% | -39.6% | -26.8% | -25.8% | |
| Earnings yield | -2.4% | -18.1% | -31.8% | -18.4% | -5.3% | |
| Free cash flow yield | -2.0% | -11.2% | -23.6% | -18.4% | -6.5% | |
| Capex / Op. cash flow | -6.4% | -3.8% | -6.8% | -8.9% | -32.0% | |
| Capex / Depreciation | 16.6% | 19.0% | 48.1% | 58.1% | 294.3% | |
| Capex / Sales | 1.1% | 2.0% | 6.3% | 8.8% | 40.0% | |
| SG&A / Sales | 60.4% | 88.0% | 101.3% | 99.4% | 110.1% | |
| R&D / Sales | 33.9% | 57.5% | 71.7% | 76.5% | 92.2% | |
| Stock comp / Sales | 18.6% | 30.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 23.5% | 22.7% | 18.8% | 14.7% | 13.8% | |
| Days sales outstanding | 66d | 85d | 81d | 79d | 41d | |
| Days payables outstanding | 33d | 37d | 37d | 51d | 24d | |
| Operating cycle | 117d | 128d | 151d | 170d | 184d | |
| Cash conversion cycle | 84d | 91d | 114d | 119d | 159d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+179.2%EV / Sales ▲+87.0%EV / EBITDA ▼-1148.4%EV / Op. cash flow ▼-48.444Earnings yield ▲+0.157
Profitability
Return on equity ▲+0.515Return on assets ▲+0.180Return on invested capital ▲+0.229Return on capital employed ▲+0.233Operating ROA ▲+0.162Income quality ▲+0.176Tax burden ▲+0.001
Efficiency
Days sales outstanding ▼-18.743Days payables outstanding ▼-3.710Operating cycle ▼-11.253Cash conversion cycle ▼-7.543Capex / Sales ▼-0.010R&D / Sales ▼-0.237
Balance-sheet strength
Current ratio ▲+0.445Net debt / EBITDA ▼-6.717Working capital ▲+24571000.000Invested capital ▲+3212000.000Intangibles / Total assets ▲+0.008
Change over 5 years
Valuation
Market cap ▼-37.4%EV / Sales ▼-61.9%EV / EBITDA ▼-342.9%EV / Op. cash flow ▼-37.856Earnings yield ▲+0.028
Profitability
Return on equity ▲+0.071Return on assets ▲+0.108Return on invested capital ▲+0.126Return on capital employed ▲+0.123Operating ROA ▲+0.096Income quality ▼-0.157Tax burden ▲+0.001
Efficiency
Days sales outstanding ▲+25.202Days payables outstanding ▲+8.595Operating cycle ▼-67.183Cash conversion cycle ▼-75.778Capex / Sales ▼-0.389R&D / Sales ▼-0.584
Balance-sheet strength
Current ratio ▼-0.200Net debt / EBITDA ▼-7.180Working capital ▼-78671000.000Invested capital ▼-183688000.000Intangibles / Total assets ▲+0.097
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-02-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-29 Algert Global LLC Has $2.83 Million Position in Adaptive Biotechnologies Corporation $ADPT Algert Global LLC decreased its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 63.7% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 131,830 shares of the company''s stock after selling 230,880 shares during the quarter. Algert Global LLC owned 0.08% of Adaptive
- 2026-08-17 Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode
- 2026-08-14 Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT Dimensional Fund Advisors LP lowered its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 86.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 188,338 shares of the company''s stock after selling 1,194,586 shares during the quarter. Dimensional
- 2026-07-31 Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the spin-off of Immune Medicine revealing strong underlying profitability. MRD revenue grew 49% year-over-year (excluding milestones), sequencing gross margins exceeded 70%, and adjusted EBITDA margin reached 14%, supporting a high-growth, high-quality earnings profile. Refinancing eliminated a 5% perpetual revenue burden, while the planned separation of Immune Medicine should clarify earnings and remove $6M in quarterly adjusted EBITDA losses.
- 2026-07-31 Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue? Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company''s fundamentals for clues.
- 2026-07-30 Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript
- 2026-07-29 Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 2026-07-29 Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago.
- 2026-07-29 Adaptive Biotechnologies Q2 Earnings Call Highlights Adaptive Biotechnologies NASDAQ: ADPT reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year revenue outlook. The company also outlined further steps toward separating its Immune Medicine operation and strengthened its balance sheet through a $340 million convertible note offering.
- 2026-07-29 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2026.